Article
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Oncogene - 1 Aug 2018
Berns Katrien, Caumanns Joseph J, Hijmans E Marielle, Gennissen Annemiek M C, Severson Tesa M, Evers Bastiaan, Wisman G Bea A, Jan Meersma Gert, Lieftink Cor, Beijersbergen Roderick L, Itamochi Hiroaki, van der Zee Ate G J, de Jong Steven, Bernards René
Abstract excerpt
Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational approach to target ovarian clear cell cancers with ARID1A mutations, we performed kinome-centered lethality screens...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.